Nuformix (LON:NFX) Shares Up 6.7% – Still a Buy?
by Mitch Edgeman · The Markets DailyNuformix plc (LON:NFX – Get Free Report)’s stock price traded up 6.7% during mid-day trading on Tuesday . The stock traded as high as GBX 0.19 and last traded at GBX 0.19. Approximately 1,201,807 shares were traded during mid-day trading, a decline of 97% from the average session volume of 35,847,605 shares. The stock had previously closed at GBX 0.18.
Nuformix Stock Performance
The firm has a fifty day simple moving average of GBX 0.18 and a 200 day simple moving average of GBX 0.22. The company has a market capitalization of £5.01 million, a PE ratio of -6.55 and a beta of 1.54.
Nuformix (LON:NFX – Get Free Report) last released its quarterly earnings data on Thursday, May 28th. The company reported GBX (0.02) earnings per share (EPS) for the quarter.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.